At a glance
ClinicalIndex Comparison RecordPhase 2Withdrawn· 0 enrolled
Drug / intervention
LC-CTLsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Interventional Treatment of Lung Cancer (LC) With LC Specific Immune Lymphocytes (LC-CTLs)
In Brief
A Phase 2 clinical trial evaluating LC-CTLs for Lung Cancer and NSCLC. Withdrawn before enrollment, across 1 site.
Signals
Trial was withdrawn before enrollment
Detailed Summary
The primary objective of this study is to evaluate the safety of lung cancer specific cytotoxic lymphocytes (LC-CTLs). The secondary objectives are to evaluate the rate of successful LC-CTLs generation in vitro and determine the anti-lung cancer efficacy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer, NSCLC
CountriesChina
Collaborators--
Timeline
Phase 2WithdrawnFinished
201820192020202120222023202420252026
Enrollment StartNov 2017
First PostedNov 2017
Primary CompletionJan 2019
Study CompletionDec 2020
TodayJul 2026
First PostedNov 27, 2017
Enrollment StartNov 15, 2017
Primary CompletionJan 1, 2019
Study CompletionDec 1, 2020
TodayJul 1, 2026
Enrollment to primary: 1.1 yearsPosted 8.6 years ago
Interventions
LC-CTLsbiological
2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg via IV, chest or tumor injection each time